The value of pharma schemes rose as investors shifted focus to drugmakers, considered defensive in uncertain times. As per data from Value Research the mid-cap category offered the highest return of 8.93%, followed by multi-caps which returned 7.88%.
Tesla’s $584 billion wipeout: 4 forces behind the EV giant’s accelerating 45% stock car
Tesla’s lead in EV infrastructure is at risk. In March, Chinese competitor BYD launched a next-gen fast-charging station that provides 400 kilometers (around 250 miles)
April 9, 2025